Caso-Maestro, OscarJiménez-Romero, CarlosJusto-Alonso, IagoCalvo-Pulido, JorgeLora-Pablos, DavidMarcacuzco-Quinto, AlbertoCambra-Molero, FélixGarcía-Sesma, AlvaroPérez-Flecha, MarinaMuñoz-Arce, CarlosLoinaz-Segurola, CarmeloManrique-Municio, Alejandro2025-01-072025-01-072018https://hdl.handle.net/10668/25473To increase the number of available grafts. This is a single-center comparative analysis performed between April 1986 and May 2016. Two hundred and twelve liver transplantation (LT) were performed with donors ≥ 70 years old (study group). Then, we selected the first cases that were performed with donors Graft and patient survivals were similar between both groups without increasing the risk of complications, especially primary non-function, vascular complications and biliary complications. We identified 5 risk factors as independent predictors of graft survival: recipient hepatitis C virus (HCV)-positivity [hazard ratio (HR) = 2.35; 95% confidence interval (CI): 1.55-3.56; P = 0.00]; recipient age (HR = 1.04; 95%CI: 1.02-1.06; P = 0.00); donor age X model for end-stage liver disease (D-MELD) (HR = 1.00; 95%CI: 1.00-1.00; P = 0.00); donor value of serum glutamic-pyruvic transaminase (HR = 1.00; 95%CI: 1.00-1.00; P = 0.00); and donor value of serum sodium (HR = 0.96; 95%CI: 0.94-0.99; P = 0.00). After combining D-MELD and recipient age we obtained a new scoring system that we called DR-MELD (donor age X recipient age X MELD). Graft survival significantly decreased in patients with a DR-MELD score ≥ 75000, especially in HCV patients (77% vs 63% at 5 years in HCV-negative patients, P = 0.00; and 61% vs 25% at 5 years in HCV-positive patients; P = 0.00). A DR-MELD ≥ 75000 must be avoided in order to obtain the best results in LT with donors ≥ 70 years old.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/Aged donorsDonor ageLiver transplantationMarginal donorsOld donorsAdultAge FactorsAgedAged, 80 and overCase-Control StudiesDonor SelectionEnd Stage Liver DiseaseFemaleGraft SurvivalHepacivirusHumansLiver TransplantationMaleMiddle AgedPrognosisSeverity of Illness IndexTissue DonorsYoung Adultresearch article30598583open access10.3748/wjg.v24.i47.53912219-2840PMC6305532https://doi.org/10.3748/wjg.v24.i47.5391https://pmc.ncbi.nlm.nih.gov/articles/PMC6305532/pdf